Mobocertinib Global Maximum-Tolerated Dose is Found Tolerable in Japanese Patients With NSCLC
September 16th 2021Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts, leading to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in Japanese patients with non–small cell lung cancer.
OS Improves With Addition of Ribociclib/Endocrine Therapy in Advanced Breast Cancer
July 8th 2021Regardless of age the combination of ribociclib and endocrine therapy led to improved overall survival in pre- or postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Nivolumab/Ipilimumab Triplet Improves OS in Advanced NSCLC Compared With Chemotherapy Alone
June 21st 2021A frontline regimen nivolumab, ipilimumab, and 2 cycles of chemotherapy yielded an improvement in overall survival versus chemotherapy alone in patients with advanced non–small cell lung cancer. The benefit was observed regardless of tumor mutational burden status in the tissue or blood.
Transfusion Independence at 24 Weeks Linked to Improved OS on Momelotinib in Myelofibrosis
June 11th 2021Subgroup analyses from the the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials show that achievement of transfusion independence by the 24th week of treatment is associated with an improvement in overall survival compared with continued transfusion dependence at that time point.
Tisagenlecleucel Elicits Impressive and Durable Responses in Relapsed/Refractory Follicular Lymphoma
June 7th 2021In the phase 2 ELARA trial, treatment with the autologous CD19-directed chimeric antigen receptor T-cell therapy, tisagenlecleucel, achieved a high response rate that appeared durable, in patients with relapsed/refractory follicular lymphoma.
Fulvestrant Alone Found to be Superior to Venetoclax/Fulvestrant Combo in ER+/HER2- Breast Cancer
June 5th 2021Compared to fulvestrant alone, venetoclax and fulvestrant did not improve overall outcomes in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer who had previously received a CDK4/6 inhibitor.
Long-Term Efficacy of Brigatinib Sustained in Crizotinib-Refractory ALK+ NSCLC
June 4th 2021According to results from the phase 1/2 and phase 2 ALTA trials, brigatinib demonstrated sustained long-term responses and survival in patients with crizotinib-refractory ALK-positive non–small cell lung cancer.
Tazemetostat Elicits Preclinical Anti-Tumor Responses in MCL Cell Lines With BTK Resistance
May 26th 2021Mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors displayed anti-tumor activity on treatment with tazemetostat as monotherapy or in combination with zanubrutinib, according to data from a preclinical analysis.
Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC
February 24th 2021In with EGFR-mutant non–small cell lung cancer and brain metastases, oral osimertinib achieved rapid, high, and uniform brain exposure which was followed reduction in total brain metastases volume, according to results from the phase 1 ODIN-BM study.
Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC
January 31st 2021Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.
Urelumab Combo Leads to Improved Pathologic Response in Resectable PDAC
January 25th 2021Improved antitumor activity of the triplet combination of urelumab, a GVAX vaccine, and nivolumab was observed in patients with resectable pancreatic ductal adenocarcinoma, according to findings from a 3-arm phase 1/2 trial.
Survival Benefit Maintained With Atezolizumab Plus Bevacizumab in Advanced HCC
January 17th 2021Results from the phase 3 IMbrave150 clinical trial showed that the combination of atezolizumab and bevacizumab continued to demonstrate improvement in survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.
Novel CDK4/6 Inhibitor Combos Shape Future for HR+/HER2– Breast Cancer
December 30th 2020Despite the success of CDK4/6 inhibitors in patients with advanced hormone receptor–positive, HER2-negative breast cancer, acquired resistance develops in many. For these patients, research indicates that treatment sequencing may soon include agents that act on implicated pathways of resistance.
Ipatasertib Plus Paclitaxel Combo Fails to Improve PFS in PIK3CA/AKT1/PTEN-Altered TNBC
December 11th 2020Ipatasertib in combination with paclitaxel failed to demonstrate a significant improvement in progression-free survival compared with placebo plus paclitaxel as treatment of patients with PIK3CA/AKT1/PTEN-altered locally advanced, unresectable or metastatic triple-negative breast cancer.
Premenopausal Women With Lymph Node+, HR+/HER2- Breast Cancer Benefit From Chemotherapy Addition
December 9th 2020Five-year invasive disease-free survival and overall survival were improved with the addition of chemotherapy to endocrine therapy as treatment of premenopausal, but not postmenopausal, women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer and a recurrence score between 0 and 25.
High-/Low-Dose Sabatolimab Exhibit Comparable Pharmacokinetics in MDS and AML
December 6th 2020In patients with acute myeloid leukemia and myelodysplastic syndrome, treatment with sabatolimab administered at 200 mg every 2 weeks and 800 mg every 4 weeks demonstrated similar pharmacokinetic activity, according to findings from a dose-selection and dose-response analysis presented during the 2020 American Society of Hematology Annual Meeting.